Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.